Espero BioPharma to Present at BIO CEO & Investor Conference on February 13, 2018

Jacksonville, FL and Irvine, CA – February 7, 2018 – Espero BioPharma, a platform biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced that Chairman and CEO Quang Pham will present at the BIO CEO & Investor Conference on Tuesday, February 13th, 2018 at 10:00 AM ET. The conference will be held …

Area company Espero looks to hold trials for new drugs

Jacksonville, FL – January 3, 2018 (The Florida Times Union) – In 2014 Quang Pham founded Espero Pharmaceuticals, which the Jacksonville Business Journal called “the fastest-growing company in Jacksonville” last year. Now the company, renamed Espero BioPharma after a merger, is preparing to launch new clinical trials for two drugs Pham, its chairman and CEO, believes can become “standards of …

Espero BioPharma to Present at Biotech Showcase on January 9, 2018

Jacksonville, FL and Irvine, CA – January 3, 2018 — Espero BioPharma, a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced that Chairman and CEO Quang Pham will present at the Biotech Showcase 2018 on January 9th, 2018 at 11:45 AM PT / 2:45 PM ET. The conference will be held …

Espero BioPharma Provides Corporate Update and 2018 Objectives

JACKSONVILLE, Fla. and IRVINE, Calif., Dec. 12, 2017 (GLOBE NEWSWIRE) — Espero BioPharma, a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat cardiovascular diseases, today announced a strategic update on its clinical and regulatory strategies for tecarfarin, an oral anticoagulant (OAC). Tecarfarin and budiodarone were added to Espero’s product pipeline through the company’s merger with …

Espero BioPharma named as fastest-growing private company in Northeast Florida

JACKSONVILLE, Fla, July 26, 2017 –The Jacksonville Business Journal has named Espero BioPharma as the fastest-growing private company in Northeast Florida. The ranking is based on the company’s average annual revenue growth over the past three years. Logistics, finance, health care, technology, law and more — all of the major industries in the Greater Jacksonville area are represented on this …

Espero Pharmaceuticals and Armetheon to Merge and Create a 
Premier Cardiovascular Focused Biopharmaceutical Company

JACKSONVILLE, Fla. and MENLO PARK, Calif. (March 30, 2017) – Espero Pharmaceuticals, Inc., a privately held, commercial-stage cardiovascular pharmaceutical company, and Armetheon, Inc., a privately held, late-clinical stage pharmaceutical company developing innovative novel drugs addressing major unmet needs in cardiovascular diseases, today announced their plans to merge. Upon completion of the merger, which is expected to occur in the second …

Armetheon Announces European Medicines Agency’s Support for 1000 Patient Single Phase 3 Study prior to MAA Filing for its Novel Oral Anticoagulant Tecarfarin

MENIO PARK, Calif., Feb. 14, 2017 /PRNewswire/ – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced it has received advice from the European Medicines Agency (EMA) Scientific Advice Working Group (SAWG) for the development of its novel oral anticoagulant tecarfarin. The SAWG advised that Armetheon can conduct a single1000 patient pivotal study prior …

Armetheon announces issuance of a new U.S. patent for its Phase 2 clinical stage novel oral antiarrhythmic budiodarone

MENIO PARK, Calif., Feb. 13, 2017 – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced the issuance on January 24, 2017 by the U.S. Patent and Trademark Office (USPTO) of a new patent covering the company’s novel oral antiarrhythmic, budiodarone, the only known novel anti-arrhythmic in clinical development. The new U.S. Patent No. …

Espero Acquires DURLAZA® (aspirin) Extended Release Capsules 
for Secondary Prevention of Stroke and Acute Cardiac Events

JACKSONVILLE, Fla. (February 7, 2017) – Espero Pharmaceuticals, Inc., a commercial-stage cardiovascular pharmaceutical company, today announced that the company has acquired the global rights to DURLAZA® (aspirin) Extended Release Capsules.Company officials will provide an update on February 13, 2017 at the BIO CEO & Investor Conference held at the Waldorf Astoria New York. DURLAZA is an FDA-approved and commercially available …

GONITRO™ to Participate in First-of-its-Kind 
Comparative Effectiveness ISCHEMIA Clinical Trial Sponsored by the National Institutes of Health

JACKSONVILLE, Fla. (Jan. 19, 2017) – Espero Pharmaceuticals, Inc., a commercial-stage cardiovascular pharmaceutical company, will donate GONITRO™ (nitroglycerin sublingual powder) to the ongoing International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) clinical trial and to the ISCHEMIA-Chronic Kidney Disease (CKD) ancillary trial. The company’s executives provided an update during last week’s annual JP Morgan Healthcare Conference …